Abstract
There is now a lot of discussion on less than three doses for Human Papillomavirus (HPV) vaccination and, most probably, the immunity for an “aluminum-only” adjuvanted vaccine would be weaker. The HPV “late” L1 antigen seems to be not of good quality for the quadrivalent vaccine, and therefore L1 should not be a basis for argumentation in favor of a one-dose. We really doubt a “one-dose” proposal to be acceptable for HPV lesion control; certainly, it could be possible for lower response antigens like HPV 18, 11, and 6 with an aluminum-based formulation only. More importantly, the message suggested for a one-dose could well be a very bad one as the waning of immunity could have important clinical implications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
